Clinical trials: Second Line Treatment
Small Cell Lung Cancer
Docetaxel - Carboplatin As Second Line Treatment in Patients with Small Cell Lung Cancer
Phase II studies with docetaxel in first line - and second line treatment of SCLC demonstrated that docetaxel is an active agent in these patient groups.
- Trial name
- DOCAR (NCT00686985)
- Testing
- Carboplatin, docetaxel
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Dr. B. Biesma
Small Cell Lung Cancer (SCLC)
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
SCLC has short doubling time, high proliferation rate and early widespread metastasis. Most patients with SCLC have hematogenous metastasis. SCLC is highly sensitive to initial chemoradiotherapy, but the recurrence rate is high.
- Trial name
- NCT05027100
- Testing
- Anlotinib Tislelizumab Irinotecan
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Haibo Zhang
HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical trials in patients with metastatic triple negative breast cancer (mTNBC)…
- Conditions
- HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer, HR+ HER2 Breast Cancer
- Trial name
- ENCORE (NCT06774027)
- Testing
- Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Participants Who Had Received Second-line or Higher Advanced Melanoma and Advanced Renal Cancer
Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer
Safety and efficacy of Cardonilmab as a second-line or above treatment in patients with advanced malignant melanoma and renal cell carcinoma.
- Trial name
- NCT06670300
- Testing
- cardonilimab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- YongZhang
Neoplasms
A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer
The purpose of this study is to evaluate the efficacy and toxicity of irinotecan with dabrafenib, cetuximab/panitumumab in the second line of treatment for the potential treatment of colorectal cancer that: has a metastatic…
- Trial name
- NCT06967155
- Testing
- • Drug: Dabrafenib • Drug: Trametinib • Drug: Cetuximab • Drug: Рanitumumab • Drug: Oxaliplatin • Drug: Irinotecan • Drug: Leucovorin • Drug: 5-FU
- Where
- Russia
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Blokhin's Russian Cancer Research Center
Non-small Cell Lung Cancer
Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)
evaluate Erlotinib efficacy and safety as the 2nd/3rd line treatment in advanced or recurrent NSCLC with EGFR wild type and without c-met expression
- Trial name
- NCT02006043
- Testing
- Erlotinib 150mg
- Where
- 2 sites in China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Li Zhang
Helicobacter
Comparison of the Levofloxacin Sequential Therapy and Quadruple Therapy in Second Line Treatment for HP
Objectives: Eradication of H. pylori infection could reduce the occurence or recurrence of gastric cancer and peptic ulcer diseases.
- Trial name
- NCT03148366
- Testing
- Levofloxacin based sequential therapy, bismuth quadruple therapy for 10 days (BQ)
- Where
- 2 sites in Taiwan
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Advanced Renal Cell Carcinoma
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
The study consists of two parts, the first part is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy as…
- Trial name
- NCT05522231
- Testing
- fruquintinib+sintilimab, axitinib / everolimus, fruquintinib
- Where
- 48 sites in China
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Helicobacter Pylori Infection
Sequential Versus Quadruple Therapy in the Second-line Treatment
Objectives: A recent randomized trial showed that 14-day sequential therapy containing high dose proton pump inhibitor was higher than 95% in the first line treatment.
- Trial name
- NCT03208426
- Testing
- Esomeprazole (S14), Esomeprazole (BQ10), Amoxicillin (ST14)
- Where
- Taiwan
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Esophageal Cancer
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
The purpose of this study is to observe and evaluate the efficacy and safety of Anti-PD-1 antibody SHR-1210 plus apatinib versus SHR-1210 as second-line treatment of advanced esophageal squamous cell.
- Trial name
- NCT05049681
- Testing
- Camrelizumab, Apatinib
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Feng Wang
Smoking Cessation, Harm Reduction
Evaluate Harm Reduction Products as a Second Line Intervention for Adult Smokers Who Do Not Quit With NRT
This study will determine whether a range of products along the reduced-risk continuum can reduce smoke exposure for individuals who fail to quit smoking using current medically approved nicotine replacement therapy (NRT)…
- Trial name
- NCT06088862
- Testing
- Nicoderm, Nicorette 4Mg Chewing Gum, Nicorette Lozenge Product
- Where
- 2 sites in United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Advanced Colorectal Cancer
Second-line Surufatinib Combined With Chemotherapy in Advanced CRC
A phase II, muti-cohort study to assess the efficacy and safety of Surufatinib combined with chemotherapy as a second-line treatment in patients with advanced CRC
- Trial name
- NCT04734249
- Testing
- Surufatinib(HMPL-012)
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Fujian Cancer Hospital
Helicobacter Infection
The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori
As increasing the antibiotics resistance, the effectiveness of traditional Helicobacter pylori (H. pylori) therapies has been declined coincidently. In this study, the investigators evaluated the efficacy of H.
- Trial name
- NCT02349685
- Testing
- H. pylori culture and antimicrobial susceptibility test, 14 day PBMT group, 14 day MEA group
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Helicobacter
Sequential Therapy Versus Quadruple Therapy in H. Pylori Eradication
The investigators aimed to 1. compare the eradication rates and long term re-infection rates of sequential therapy for 14 days versus bismuth quadruple therapy for 10 days in the first line and second line treatment 2.
- Trial name
- NCT03156855
- Testing
- 14-day sequential therapy, Bismuth quadruple therapy
- Where
- 7 sites in Taiwan
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Metastatic Triple-negative Breast Cancer
Saci Nivo Rela for TNBC
This is a randomized, open-label, phase Ib study to assess safety and efficacy of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus a fixed dose combination of nivolumab and relatlimab in patients with any…
- Trial name
- SIMONE (NCT06963905)
- Testing
- Relatlimab FDC + Nivolumab, Sacituzumab Govitecan (SG), Nivolumab
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yale University
Healthy
Clinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis Agents
This study aims to investigate the pharmacokinetic characteristics of second-line anti-tuberculosis agents after oral/intramuscular administration in healthy male volunteers.
- Trial name
- NCT02128308
- Testing
- Levofloxacin and Streptomycin added, Moxifloxacin and Kanamycin added
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Initial Efficacy of Quit Line, Efficacy of Secondary Reengagement Intervention
Enhancing the Efficacy of Smoking Quit Line in the Military (AFIII Renewal)
This study is a randomized clinical trial designed to measure the effectiveness of three QL interventions for smokers who failed to quit an initial smoking cessation intervention, but remain motivated to quit smoking.
- Trial name
- Freedom (NCT02201810)
- Testing
- Rate reduction intervention, Recycling Group, Choice Group
- Where
- United States
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- University of Virginia